|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/12/16 Idt Corp 10-Q 10/31/16 68:3.3M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 307K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
12: R1 Document and Entity Information HTML 39K
13: R2 Consolidated Balance Sheets HTML 125K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
15: R4 Consolidated Statements of Income (Unaudited) HTML 78K
16: R5 Consolidated Statements of Comprehensive Income HTML 43K
(Unaudited)
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 115K
18: R7 Basis of Presentation HTML 24K
19: R8 Zedge Spin-Off HTML 28K
20: R9 Investment in Cornerstone Pharmaceuticals, Inc. HTML 28K
21: R10 Marketable Securities HTML 58K
22: R11 Fair Value Measurements HTML 40K
23: R12 Derivative Instruments HTML 39K
24: R13 Equity HTML 49K
25: R14 Earnings Per Share HTML 34K
26: R15 Revolving Credit Loan Payable HTML 24K
27: R16 Accrued Severance Expense HTML 21K
28: R17 Accumulated Other Comprehensive Loss HTML 29K
29: R18 Business Segment Information HTML 44K
30: R19 Commitments and Contingencies HTML 45K
31: R20 Other Income (Expense), Net HTML 26K
32: R21 Income Taxes HTML 23K
33: R22 Recently Issued Accounting Standard Not Yet HTML 32K
Adopted
34: R23 Zedge Spin-Off (Tables) HTML 23K
35: R24 Marketable Securities (Tables) HTML 58K
36: R25 Fair Value Measurements (Tables) HTML 29K
37: R26 Derivative Instruments (Tables) HTML 29K
38: R27 Equity (Tables) HTML 33K
39: R28 Earnings Per Share (Tables) HTML 33K
40: R29 Accumulated Other Comprehensive Loss (Tables) HTML 25K
41: R30 Business Segment Information (Tables) HTML 34K
42: R31 Commitments and Contingencies (Tables) HTML 25K
43: R32 Other Income (Expense), Net (Tables) HTML 24K
44: R33 Zedge Spin-Off (Details) HTML 26K
45: R34 Investment in Cornerstone Pharmaceuticals, Inc. HTML 76K
(Details)
46: R35 Marketable Securities (Details) HTML 64K
47: R36 Marketable Securities (Details 1) HTML 34K
48: R37 Marketable Securities (Details 2) HTML 39K
49: R38 Marketable Securities (Details Textual) HTML 27K
50: R39 Fair Value Measurements (Details) HTML 30K
51: R40 Fair Value Measurements (Details Textual) HTML 22K
52: R41 Derivative Instruments (Details) HTML 21K
53: R42 Equity (Details) HTML 59K
54: R43 Equity (Details Textual) HTML 52K
55: R44 Earnings Per Share (Details) HTML 32K
56: R45 Earnings Per Share (Details 1) HTML 21K
57: R46 Revolving Credit Loan Payable (Details) HTML 46K
58: R47 Accrued Severance Expense (Details) HTML 26K
59: R48 Accumulated Other Comprehensive Loss (Details) HTML 33K
60: R49 Business Segment Information (Details) HTML 39K
61: R50 Business Segment Information (Details Textual) HTML 19K
62: R51 Commitments and Contingencies (Details) HTML 28K
63: R52 Commitments and Contingencies (Details Textual) HTML 38K
64: R53 Other Income (Expense), Net (Details) HTML 33K
65: R54 Income Taxes (Details) HTML 23K
67: XML IDEA XML File -- Filing Summary XML 117K
66: EXCEL IDEA Workbook of Financial Reports XLSX 58K
6: EX-101.INS XBRL Instance -- idt-20161031 XML 813K
8: EX-101.CAL XBRL Calculations -- idt-20161031_cal XML 135K
9: EX-101.DEF XBRL Definitions -- idt-20161031_def XML 362K
10: EX-101.LAB XBRL Labels -- idt-20161031_lab XML 914K
11: EX-101.PRE XBRL Presentations -- idt-20161031_pre XML 581K
7: EX-101.SCH XBRL Schema -- idt-20161031 XSD 124K
68: ZIP XBRL Zipped Folder -- 0001213900-16-019309-xbrl Zip 93K
EXHIBIT 32.1
Certification Pursuant to
18 U.S.C. Section 1350
(as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act Of 2002)
In connection with the Quarterly Report of IDT Corporation (the “Company”) on Form 10-Q for the quarter ended October 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Shmuel Jonas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 12, 2016
| /s/ Shmuel Jonas | |
|
Shmuel Jonas Chief Executive Officer |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to IDT Corporation and will be retained by IDT Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 12/12/16 | |||
| For Period end: | 10/31/16 | 4 | ||
| List all Filings | ||||